Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

and Eli Lilly’s Zepbound (tirzepatide). At that time, eight-week data from the trial in around 40 subjects pointed to a 4.7% reduction in weight, which Structure said was clinically meaningful ...

However, unlike Wegovy and Ozempic, Zepbound also imitates the structure of a second hormone, known as gastric inhibitory polypeptide, or GIP. More From Newsweek Vault: What Is a Health Savings ...

Zepbound™ is an appetite suppressant that ... Whether you have insurance or not, PlushCare has a pricing structure designed to fit diverse financial situations, making it easier for everyone ...

Sudden weakness, slurred speech, visual disturbances, or stroke. Dyslipidemia can cause plaque to build up in the arteries ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...

New Drugs on the Horizon to Challenge Novo Nordisk and Eli Lilly Novo Nordisk and Eli Lilly have set the bar for efficacy and ...

In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor ...

BTC's implied volatility curve shows a noticeable kink on Oct. 5, signaling expectations for an unusually volatile Saturday.